Compounded GLP-1 Rules 2026 - What Changed After the FDA Shortage Ended

For roughly two years, compounded semaglutide and tirzepatide were the answer to an obvious problem: brand-name GLP-1s cost around $1,000 a month, insurance largely excluded them, and both drugs were in shortage. Federal law allows compounding of drugs on the FDA shortage list, and an entire telehealth industry was built on that foundation.

That foundation changed. Both molecules came off the shortage list, and with them went the specific, broad legal basis that permitted routine compounding of copies. Compounding still occurs in narrower circumstances, but the landscape is materially different from what it was — and many patients on compounded medication have not been told.

What This Article Is and Is Not

This is a plain-language summary of a genuinely complex regulatory situation, written for patients rather than lawyers. It is not legal advice, and the specifics continue to evolve through FDA action and litigation.

The practical takeaway is not ’stop taking compounded medication’. It is that provider selection now carries more weight than it did, and that there are specific questions you should be asking.

What Actually Changed

The Shortage Basis

US law permits compounding pharmacies to prepare copies of commercially available drugs under limited circumstances, and a drug appearing on the FDA drug shortage list is one of the clearest. While semaglutide and tirzepatide were in shortage, compounding copies was straightforwardly permitted.

Both drugs were subsequently removed from the shortage list — tirzepatide first, then semaglutide. Removing a drug from that list removes the shortage-based justification for compounding copies of it.

What Continues

Compounding did not stop. Pharmacies continue to prepare GLP-1 formulations, and providers describe the basis for this in various ways — commonly involving personalization for individual patient needs, such as different dosing or combination with other ingredients, which occupies different legal territory from producing straight copies.

This is precisely why many providers moved to ’personalized formulation’ language — combining GLP-1s with B12, B6 or other additives. Whether any given arrangement is appropriate is a question about that specific pharmacy and that specific prescription, not something a patient can determine from a website.

FDA Enforcement Activity

The FDA has been publicly active here. It has published concerns about unapproved GLP-1 drugs used for weight loss, including instances of telehealth companies marketing unapproved compounds such as retatrutide directly to consumers, and has issued warnings to telehealth companies over promotional claims. Reporting has described the FDA sending warnings to 30 telehealth companies over false promotional claims rendering products misbranded.

What Compounded Medication Is — and Is Not

	Brand-name (Wegovy, Zepbound)	Compounded semaglutide/tirzepatide
FDA approval	Yes — full review for safety and efficacy	No — not FDA-approved
Manufacturing oversight	Manufacturer under FDA cGMP	Varies by pharmacy tier (503A vs 503B)
Active ingredient	Manufacturer-produced	Sourced by the compounding pharmacy
Clinical trial evidence	Extensive, product-specific	None for the compounded preparation itself
Lot traceability and recalls	Full manufacturer pharmacovigilance	Varies by pharmacy
Typical cost	$149–$699/month	$70–$399/month
Insurance coverage	Sometimes	Essentially never

503A vs 503B — Why It Matters

503A pharmacies compound medications for individual patient prescriptions. They are primarily state-regulated and are not required to follow FDA current good manufacturing practice requirements.

503B outsourcing facilities register with the FDA, must comply with cGMP requirements, and are subject to FDA inspection. This is the higher-oversight tier.

Neither produces an FDA-approved product. But if two providers are close on price, the one sourcing from a 503B facility is generally the safer choice — and a provider that discloses its tier without being asked is telling you something useful about how it operates.

What This Means If You Are Currently on Compounded Medication

Do Not Stop Abruptly Without Talking to Your Clinician

Nothing in this regulatory shift is a reason to stop treatment suddenly on your own. Discontinuing GLP-1 therapy has its own consequences, including appetite return and weight regain.

If you want to change course, discuss transition planning with your prescriber — including whether moving to a brand-name product at an equivalent dose makes sense for you.

Questions to Ask Your Provider

Which specific pharmacy dispenses my medication? A named pharmacy, not ’a licensed US compounding pharmacy’.
Is that pharmacy a 503A or a 503B facility? Both are legitimate categories; the oversight differs.
On what basis is my prescription being compounded now that the drug is not in shortage? You are entitled to a clear answer.
Is my formulation a straight copy, or is it personalized? If it includes additives such as B12 or B6, ask what dose and why.
Where does the active pharmaceutical ingredient come from? Sourcing is a legitimate question.
Is there third-party potency and sterility testing, and can I see results? Reputable operations test and will say so.
What happens if the regulatory position changes further? Ask what the provider’s transition plan is, particularly if you have prepaid for multiple months.

Answers That Should Concern You

A provider that will not name its pharmacy, cannot explain the basis for compounding, offers products that are not actually semaglutide or tirzepatide, sells anything labelled ’for research purposes only’, or requires no genuine medical consultation is not a provider you should be using — regardless of price.

The FDA has specifically warned about products marketed for research purposes and about unapproved compounds such as retatrutide being marketed to consumers.

The Economics Have Also Changed

The original argument for compounded medication was overwhelming: $200 versus $1,000 a month. That gap has narrowed substantially.

The Wegovy pill starts at $149/month self-pay through NovoCare Pharmacy, with no membership fee.
Foundayo launched from $25/month for eligible patients, with cash prices commonly around $149.
Zepbound vials start at $299/month through LillyDirect.
Mid-tier compounded providers charge $250 to $399/month — more than the brand-name oral options.

The practical implication: if you are paying $250 or more per month for compounded medication, price the brand-name channels before you renew. You may be paying more for a non-FDA-approved product than an FDA-approved one would cost.

Compounded medication still wins decisively at the bottom of the market — providers at $70 to $99 per month remain far cheaper than anything brand-name. But the middle of the compounded market is now hard to justify on price alone.

The Bottom Line

The shortage-based justification for routine compounding of semaglutide and tirzepatide ended when both left the FDA shortage list. Compounding continues in narrower circumstances, and the situation continues to evolve.

This is not a reason to stop treatment abruptly. It is a reason to ask your provider specific questions — which pharmacy, which tier, on what basis, with what testing — and to take vague answers seriously as a signal.

The price argument has weakened considerably in the middle of the market. Brand-name oral GLP-1s now start around $149 per month, which undercuts a large share of compounded providers while carrying full FDA approval.

If you stay with compounded, choose carefully. See our compounded provider ranking, which weights pharmacy transparency heavily. If you would rather move to brand-name, see our brand-name ranking.

Frequently Asked Questions

Is compounded semaglutide illegal now?

It is not accurate to say illegal. What changed is that the specific, broad basis permitting compounding of copies during a shortage no longer applies. Compounding continues in narrower circumstances, and providers describe the basis for this differently. Ask your provider directly on what basis your prescription is being compounded.

Should I stop taking my compounded medication?

Not without talking to your clinician. Discontinuing GLP-1 therapy abruptly has its own consequences including appetite return and weight regain. If you want to change course, discuss transition planning with your prescriber, including whether moving to a brand-name product makes sense.

Why do so many providers now sell GLP-1s combined with B12 or B6?

Combining a GLP-1 with additional ingredients creates a formulation that is not a straight copy of the commercially available drug, which occupies different legal territory. It is worth knowing that the weight-loss benefit of these additions is generally not established by strong evidence, and that sustained high vitamin B6 intake carries a documented risk of peripheral neuropathy — ask what dose you are receiving.

What is the difference between 503A and 503B?

503A pharmacies compound for individual patient prescriptions and are primarily state-regulated. 503B outsourcing facilities register with the FDA, must comply with current good manufacturing practice requirements, and are subject to FDA inspection. 503B is the higher-oversight tier, though neither produces an FDA-approved product.

Is compounded medication dangerous?

It is not FDA-approved, which means it has not been reviewed for safety, efficacy or manufacturing quality — that is a real difference from brand-name medication, not a technicality. Whether any specific compounded product is safe depends on the pharmacy preparing it, its sourcing, and its testing. That is exactly why the questions in this article matter.

What has the FDA actually said?

The FDA has published concerns about unapproved GLP-1 drugs used for weight loss, including telehealth companies marketing unapproved compounds such as retatrutide directly to consumers, and reporting has described warnings sent to telehealth companies over promotional claims rendering products misbranded.

Is brand-name now cheaper than compounded?

In the middle of the market, sometimes yes. Brand-name oral GLP-1s start around $149 per month while mid-tier compounded providers charge $250 to $399. At the bottom of the compounded market — $70 to $99 per month — compounded remains substantially cheaper than anything brand-name.

What should I avoid entirely?

Any product sold ’for research purposes only’, any provider that will not name its pharmacy, any GLP-1 that is not actually semaglutide or tirzepatide, and any service that prescribes without a genuine medical consultation. These are not bargains.

⚕️ Medical Disclaimer:

This article is for informational purposes only and is not medical advice, diagnosis, or treatment. GLP-1 receptor agonists are prescription medications with serious risks and contraindications, including a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.

Disclosure:

This article is a plain-language summary of a complex and evolving regulatory situation, based on publicly available FDA communications, reputable news and clinical trade reporting, and provider-published materials, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. This is not legal advice and is not a definitive statement of federal or state law, which continues to develop through regulatory action and litigation. Compounded medications are not FDA-approved and have not undergone FDA review for safety, efficacy or manufacturing quality. Nothing here is medical advice — decisions about continuing, changing or stopping treatment must be made with a licensed clinician.

Compounded GLP-1s After the Shortage Ended